0000896264-24-000180.txt : 20240723 0000896264-24-000180.hdr.sgml : 20240723 20240723161105 ACCESSION NUMBER: 0000896264-24-000180 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240723 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240723 DATE AS OF CHANGE: 20240723 FILER: COMPANY DATA: COMPANY CONFORMED NAME: USANA HEALTH SCIENCES INC CENTRAL INDEX KEY: 0000896264 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 870500306 STATE OF INCORPORATION: UT FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35024 FILM NUMBER: 241134594 BUSINESS ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 BUSINESS PHONE: 8019547100 MAIL ADDRESS: STREET 1: 3838 WEST PARKWAY BLVD. STREET 2: 3838 WEST PARKWAY BLVD. CITY: SALT LAKE CITY STATE: UT ZIP: 84120-6336 FORMER COMPANY: FORMER CONFORMED NAME: USANA INC DATE OF NAME CHANGE: 19930125 8-K 1 usna-20240723.htm 8-K usna-20240723
FALSE000089626400008962642024-07-232024-07-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
July 23, 2024
USANA HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Utah
(State or other jurisdiction of incorporation)
001-3502487-0500306
(Commission File No.)(IRS Employer
Identification No.)
3838 West Parkway Boulevard
Salt Lake City, Utah 84120
(Address of principal executive offices, Zip Code)
Registrant's telephone number, including area code: (801) 954-7100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareUSNANew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02    Results of Operations and Financial Condition.
On July 23, 2024, USANA Health Sciences, Inc. (the “Company” or “USANA”) issued a press release announcing its financial results for the second quarter ended June 29, 2024. The release also announced that the Company will post a document titled “Management Commentary” on the Company’s website and that executives of the Company will hold a conference call with investors, to be broadcast over the World Wide Web and by telephone and provided access information, date and time for the conference call. The Company noted that the call will consist of brief remarks by the Company’s management team, before moving directly into questions and answers. A copy of the press release, and the Management Commentary, are furnished herewith as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference. These documents will be posted on the Company’s corporate website, www.usana.com.
The information in this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report, including the exhibits, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.
Item 7.01    Regulation FD Disclosure
The information disclosed above under Item 2.02, as well as the exhibits attached under Item 9.01 below are incorporated herein by reference.
Item 9.01    Financial Statements and Exhibits.
(d)Exhibits


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
USANA HEALTH SCIENCES, INC.
By:/s/ G. Douglas Hekking
G. Douglas Hekking, Chief Financial Officer
Date: July 23, 2024

 EX-99.1 2 q22024earningsreleaseex9911.htm EX-99.1 Document

usanacorplogoresized1.jpg

USANA Health Sciences Reports Second Quarter 2024 Results

SALT LAKE CITY, July 23, 2024 (BUSINESS WIRE)—USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal second quarter ended June 29, 2024.

Key Financial & Operating Results
•Second quarter net sales were $213 million versus $238 million during Q2 2023.
•Second quarter diluted EPS was $0.54 as compared with $0.89 during Q2 2023.
•Company updates fiscal year 2024 net sales and diluted EPS outlook to $850 million to $880 million and $2.40 to $2.55 (previously $850 million to $920 million and $2.40 to $3.00).

Q2 2024 Financial Performance
Consolidated Results
Net Sales
$213 million
•-11% vs. Q2 2023
•-8% constant currency vs. Q2 2023
•-7% sequentially
•-6% constant currency sequentially
•-$5 million YOY FX impact, or -2%
Diluted EPS
$0.54
•-39% vs. Q2 2023
•-37% sequentially
Active Customers
468,000
•-4% vs. Q2 2023
•-5% sequentially

“Second quarter operating results were below our expectations,” said Jim Brown, President and Chief Executive Officer.

“Ongoing macroeconomic pressures in several of our key markets continue to impact consumer spending. This in turn creates challenges in our ability to attract and engage new customers and


generate sales momentum. To counter these challenges, we have made several strategic changes in our business over the past few quarters, including (i) restructuring our commercial team, (ii) heightening our focus on product innovation, (iii) increasing our efforts to engage our sales leaders with an Associate-first approach, (iv) expanding into India, and (v) evaluating more business development activities.

“Next month, we will be hosting our Americas & Europe Convention in Las Vegas, Nevada along with other Associate engagement-focused events in the back half of the year. We are also planning to offer a more robust promotional calendar throughout the remainder of the year.”

Q2 2024 Regional Results:
Asia Pacific Region
Net Sales
$171 million
•-12% vs. Q2 2023
•-9% constant currency vs. Q2 2023
•-8% sequentially
•80% of consolidated net sales
Active Customers
369,000
•-4% vs. Q2 2023
•-7% sequentially
Asia Pacific Sub-Regions
Greater China
Net Sales
$116 million
•-10% vs. Q2 2023
•-8% constant currency vs. Q2 2023
•-9% sequentially
Active Customers
250,000
•Flat vs. Q2 2023
•-9% sequentially
North Asia
Net Sales
$20 million
•-23% vs. Q2 2023
•-19% constant currency vs. Q2 2023
•-8% sequentially
Active Customers
42,000
•-18% vs. Q2 2023
•-7% sequentially
Southeast Asia Pacific
Net Sales
$35 million
•-10% vs. Q2 2023
•-7% constant currency vs. Q2 2023
•-2% sequentially
Active Customers
77,000
•-6% vs. Q2 2023
•+1% sequentially



Americas and Europe Region
Net Sales
$42 million
•-5% vs. Q2 2023
•-5% constant currency vs. Q2 2023
•-1% sequentially
•20% of consolidated net sales
Active Customers
99,000
•-4% vs. Q2 2023
•Flat sequentially

Balance Sheet and Share Repurchase Activity
The Company generated $8 million in operating cash flow during second quarter and ended the quarter with $332 million in cash and cash equivalents while remaining debt-free. The Company did not repurchase any shares during the quarter. As of June 29, 2024, the Company had approximately $62 million remaining under the current share repurchase authorization.

Fiscal Year 2024 Outlook
The Company is updating its net sales and earnings per share outlook for fiscal year 2024, as follows:
Fiscal Year 2024 Outlook
Revised RangePrevious Range
Consolidated Net Sales$850 - $880 million$850 - $920 million
Diluted EPS
$2.40 - $2.55
$2.40 - $3.00

“While we anticipated lower sequential operating results following a successful promotional period in the first quarter, lower than anticipated active customer counts negatively impacted our second quarter results,” said Doug Hekking, Chief Financial Officer. “Additionally, the strengthening of the U.S. dollar created downward pressure on both net sales and operating margin during the quarter.”

Mr. Hekking continued, “We are revising our fiscal 2024 outlook to reflect year-to-date operating results, our expectation for a continued challenging operating environment across many of our markets, higher than anticipated unfavorable currency exchange rate impact on operating results, and an increased effective tax rate. We recognize the need to continue investing in strategic initiatives while also aligning costs with sales performance. Our balance


sheet remains strong with $332 million of cash, zero debt, and we continue to generate solid cash flow.”

Management Commentary Document and Conference Call
For further information on the USANA’s operating results, please see the Management Commentary document, which has been posted on the Company’s website (http://ir.usana.com) under the Investor Relations section. USANA’s management team will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, July 24, 2024 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://ir.usana.com. The call will consist of brief opening remarks by the Company’s management team, followed by a questions and answers session.

Non-GAAP Financial Measures
The Company prepares its financial statements using U.S. generally accepted accounting principles (“GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.

About USANA
USANA develops and manufactures high-quality nutritional supplements, functional foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany, Spain, Romania, Italy, and India. More information on USANA can be found at www.usana.com.



Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with commencing operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; and the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.






Investor contact: Andrew Masuda


Investor Relations
(801) 954-7201
investor.relations@usanainc.com

Media contact: Amy Haran
Public Relations
(801) 954-7280



USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)

Quarter Ended
June 29,
2024		July 1,
2023
Net sales$212,869 $238,202 
Cost of sales40,333 43,326 
Gross profit172,536 194,876 
Operating expenses:
Associate incentives90,371 102,380 
Selling, general and administrative64,325 68,096 
Total operating expenses154,696 170,476 
Earnings from operations17,840 24,400 
Other income (expense):
Interest income2,763 2,224 
Interest expense(51)(43)
Other, net(349)229 
Other income (expense), net2,363 2,410 
Earnings before income taxes20,203 26,810 
Income taxes9,771 9,518 
Net earnings$10,432 $17,292 
Earnings per common share
Basic$0.55 $0.89 
Diluted$0.54 $0.89 
Weighted average common shares outstanding
Basic19,07319,321
Diluted19,15919,427



USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)

As of
June 29,
2024		As of
December 30,
2023
ASSETS
Current assets
Cash and cash equivalents$332,423 $330,420 
Inventories61,832 61,454 
Prepaid expenses and other current assets24,826 25,872 
Total current assets419,081 417,746 
Property and equipment, net97,686 99,814 
Goodwill16,837 17,102 
Intangible assets, net28,637 29,919 
Deferred tax assets18,190 13,284 
Other assets*
50,988 54,892 
Total assets$631,419 $632,757 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable$6,648 $10,070 
Line of credit - short term— 786 
Other current liabilities97,248 107,989 
Total current liabilities103,896 118,845 
Deferred tax liabilities4,653 4,552 
Other long-term liabilities10,662 12,158 
Stockholders' equity512,208 497,202 
Total liabilities and stockholders' equity$631,419 $632,757 


*Other assets include noncurrent inventories of $3,075 and $3,128 as of 29-Jun-24 and 30-Dec-23, respectively. Total inventories were $64,907 and $64,582 as of 29-Jun-24 and 30-Dec-23, respectively.


USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
SALES BY REGION
(in thousands)
(unaudited)



Quarter EndedChange from prior
year		Percent changeCurrency impact on
sales		% change
excluding currency
impact
June 29, 2024July 1, 2023
Asia Pacific
Greater China$115,513 54.3 %$128,749 54.1 %$(13,236)(10.3 %)$(3,085)(7.9 %)
Southeast Asia Pacific35,402 16.6 %$39,337 16.5 %(3,935)(10.0 %)(1,221)(6.9 %)
North Asia19,710 9.3 %$25,529 10.7 %(5,819)(22.8 %)(870)(19.4 %)
Asia Pacific Total170,625 80.2 %193,615 81.3 %(22,990)(11.9 %)(5,176)(9.2 %)
Americas and Europe42,244 19.8 %44,587 18.7 %(2,343)(5.3 %)(94)(5.0 %)
$212,869 100.0 %$238,202 100.0 %$(25,333)(10.6 %)$(5,270)(8.4 %)



USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
ACTIVE ASSOCIATES AND ACTIVE PREFERRED CUSTOMERS BY REGION
(unaudited)


Active Associates by Region(1)
(unaudited)
As of
June 29, 2024		As of
July 1, 2023
Asia Pacific:
Greater China68,00035.2 %71,00034.1 %
Southeast Asia Pacific52,00027.0 %57,00027.4 %
North Asia28,00014.5 %33,00015.9 %
Asia Pacific Total148,00076.7 %161,00077.4 %
Americas and Europe45,00023.3 %47,00022.6 %
193,000100.0 %208,000100.0 %


Active Preferred Customers by Region(2)
(unaudited)
As of
June 29, 2024		As of
July 1, 2023
Asia Pacific:
Greater China182,00066.2 %180,00064.5 %
Southeast Asia Pacific25,0009.1 %25,0009.0 %
North Asia14,0005.1 %18,0006.4 %
Asia Pacific Total221,00080.4 %223,00079.9 %
Americas and Europe54,00019.6 %56,00020.1 %
275,000100.0 %279,000100.0 %

(1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or resale.

(2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period. China utilizes a Preferred Customer program that has been implemented specifically for that market.

 EX-99.2 3 q22024managementcommentary.htm EX-99.2 Document

usanacorplogoresizeda.jpg

USANA Health Sciences, Inc.                         July 23, 2024
Q2 2024 Management Commentary

Key Financial & Operating Results
•Second quarter net sales were $213 million versus $238 million during Q2 2023.
•Second quarter diluted EPS was $0.54 as compared with $0.89 during Q2 2023.
•Company updates fiscal year 2024 net sales and diluted EPS outlook to $850 million to $880 million and $2.40 to $2.55 (previously $850 million to $920 million and $2.40 to $3.00).

Overview

Sales performance in the second quarter was below our expectations as ongoing macroeconomic pressures in several of our key markets continued to impact consumer spending. To maintain the appropriate annual cadence of promotions and incentives for our business, we also offered fewer promotions during the second quarter and experienced lower levels of spend per customer in certain markets. Combined, these factors made it difficult for our sales force to attract new customers and generate positive sales momentum during the quarter.

Notwithstanding the near-term challenges facing our business, we continue to generate solid cash flow and our balance sheet sheet remains robust with zero debt and $332 million of cash. This enables us the flexibility to continue to invest in strategic initiatives throughout the peaks and troughs of the business cycle, further strengthening USANA's position to drive sustainable long-term growth. We have invested in several strategic areas of our business over the past few quarters, including (i) restructuring our commercial team, (ii) heightening our focus on product innovation, (iii) increasing our efforts to engage our sales leaders with an Associate-first approach, (iv) expanding into India, and (v) continuing to pursue accretive M&A activities.



Our sales, marketing, and communications departments have been reorganized into one cohesive commercial team. This team is focused on delivering three fundamental benefits to our Associates: (1) best-in-class products, (2) an income opportunity that is simple and motivates the entrepreneur with a rewarding compensation plan, and (3) messaging that conveys product benefits and income opportunity in a simple and compelling manner. This new structure will also enable USANA to:
•Increase the value proposition of USANA to our Associates and customers by enhancing our already best-in-class products.
•Become faster and more agile in developing and releasing new products.
•Better understand specific Associate and customer needs in each of our markets to deliver a more tailored customer experience for them.
•Provide increased opportunities for Associate engagement including events, meetings, and reward trips.
•Improve USANA's compensation offering for both part and full-time entrepreneurs.

Next month, we will be hosting our Americas & Europe Convention in Las Vegas, Nevada where we plan to announce new product launches and upgrades. Strategic events going forward will continue to serve as the platform for introducing and launching our new and innovative products.

Our Associate engagement efforts during the quarter were focused on in-person events that we held throughout various markets in our Asia Pacific region. These events provide valuable educational forums for our Associates and are focused on business-building best practices. We have additional engagement-focused events in the back half of the year and plan to offer a more robust promotional calendar throughout the remainder of the year.

We will also continue to invest in building our brand and increasing our presence in India. Our brand and product offering have been embraced by customers in this new market during our first six months of operations, which has helped us attract many sales leaders, including health and business professionals, who will be instrumental to our success in India. We are encouraged by
2

the meaningful long-term opportunity this market offers and by the strong foundation we are building there.

Our business development team also remains highly active in evaluating potential M&A opportunities within the broader health and wellness space that would be additive to USANA's long-term growth strategy. Specifically, we are looking for opportunities that provide: 1) products and/or services centered on health and wellness; 2) vertical integration; 3) product and category expansion; 4) channel expansion; and 5) expansion of USANA's core competencies.

Q2 2024 Financial Performance
Consolidated Results
Net Sales
$213 million
•-11% vs. Q2 2023
•-8% constant currency vs. Q2 2023
•-$5 million YOY FX impact, or -2%
•-7% sequentially
•-6% constant currency sequentially
Diluted EPS
$0.54
•-39% vs. Q2 2023
•-37% sequentially
Active Customers
468,000
•-4% vs. Q2 2023
•-5% sequentially
Balance Sheet and Share Repurchase Activity
We generated $8 million in operating cash flow during the second quarter and ended the quarter with $332 million in cash and cash equivalents while remaining debt-free.

As of June 29, 2024, inventories were $65 million, flat compared to the year end balance in fiscal 2023. Our in-house sourcing and manufacturing capabilities provide us with better control of inventory levels and help to mitigate supply chain risks while providing a meaningful contribution to delivering the highest quality nutritional products.

We did not repurchase any shares during the quarter. As of June 29, 2024, we had approximately $62 million remaining under the current share repurchase authorization.

3

Quarterly Income Statement Discussion
Gross margin decreased 70 basis points from the prior year to 81.1% of net sales. The decrease can largely be attributed to the negative impact of foreign currency exchange rates and the loss of leverage on fixed-period costs due to lower net sales.

Associate Incentives decreased 50 basis points from the prior year to 42.5% of net sales. The decrease largely reflects lower incentive and promotional expenses in the current year quarter.

Selling, General and Administrative expenses increased 160 basis points from the prior year to 30.2% as a percentage of net sales. The relative increase is primarily due to a loss of leverage on lower year-over-year net sales. On an absolute basis, SG&A expenses, decreased $3.8 million compared to the second quarter of 2023 due, in part, to lower event and advertising-related expenses.

The year-to-date effective tax rate increased to 43.0% from the 35.5% reported in the comparable period of 2023 or 37.7% for fiscal 2023. The higher effective tax rate can be attributed primarily to: 1) China’s increased relative share of USANA’s sales portfolio, 2) A concentration of infrastructure costs in our corporate headquarters, and 3) generally softer operating performance, including the impact of unfavorable exchange rates in our other markets around the world. The revised effective tax rate for June 2024 year-to-date created a larger impact, or true up, resulting in a tax rate of 48.4% for the second quarter of 2024.

Q2 2024 Regional Results:
Asia Pacific Region
Net Sales
$171 million
•-12% vs. Q2 2023
•-9% constant currency vs. Q2 2023
•-8% sequentially
•80% of consolidated net sales
Active Customers
369,000
•-4% vs. Q2 2023
•-7% sequentially
Asia Pacific Sub-Regions
Greater China
Net Sales
$116 million
•-10% vs. Q2 2023
•-8% constant currency vs. Q2 2023
4

•-9% sequentially
Active Customers
250,000
•Flat vs. Q2 2023
•-9% sequentially
North Asia
Net Sales
$20 million
•-23% vs. Q2 2023
•-19% constant currency vs. Q2 2023
•-8% sequentially
Active Customers
42,000
•-18% vs. Q2 2023
•-7% sequentially
Southeast Asia Pacific
Net Sales
$35 million
•-10% vs. Q2 2023
•-7% constant currency vs. Q2 2023
•-2% sequentially
Active Customers
77,000
•-6% vs. Q2 2023
•+1% sequentially
Greater China: Net sales and local currency sales in mainland China decreased 11% and 8% year-over-year, respectively. Active Customers in this market were flat year-over-year. Sequentially, regional performance was impacted by our mainland China market, where both net sales and Active Customers decreased 9%. The primary driver of year-over-year and sequential performance is attributable to a lower level of promotional activity during the quarter.
North Asia: Net sales and local currency sales in South Korea declined 23% and 19% year-over-year, respectively, and Active Customers declined 16%. On a sequential basis, net sales and local currency sales declined 8% and 5%, respectively, while Active Customers declined 5%. Both year-over-year and sequential quarter declines reflect ongoing challenges in the local economy, which continue to negatively impacting consumer spending, thus making it difficult to attract new customers.
Southeast Asia Pacific: Net sales and local currency sales in Malaysia increased 1% and 6% year-over-year, respectively, while Active Customers declined 4% year-over-year. Sequentially, net sales and Active Customers in Malaysia increased 6% and 4%, respectively. We are encouraged to see some stabilization in our operating results in Malaysia. In the Philippines, net sales and local currency sales declined 32% and 29% year-over-year, respectively, while Active Customers were 18% lower. Sequentially, net sales and local currency sales in the Philippines
5

declined 9% and 6%, respectively, while Active Customers were flat. A difficult operating environment, highlighted by economic pressures, continues to negatively impact our operating results in the Philippines.
Americas and Europe Region
Net Sales
$42 million
•-5% vs. Q2 2023
•-5% constant currency vs.Q2 2023
•-1% sequentially
•20% of consolidated net sales
Active Customers
99,000
•-4% vs. Q2 2023
•Flat sequentially

Americas and Europe Region: Net sales in Canada decreased 1% from the prior year while local currency sales grew 1%. Active Customers in this market increased 3%. Net sales in the United States declined 10% and Active Customers decreased 7% on a year-over-year basis. Sequentially, net sales and local currency sales in Canada grew 2% and 3%, respectively, while Active Customers increased 3%. In the United States, net sales declined 3% sequentially while Active Customers were 2% lower. We continue to see price-sensitivity amongst consumer in these two markets, however, we are encouraged by the stabilizing trends over the past few quarters.

Fiscal Year 2024 Outlook
The Company is updating its net sales and earnings per share outlook for fiscal year 2024, as follows:
Fiscal Year 2024 Outlook
Revised RangePrevious Range
Consolidated Net Sales$850 - $880 million$850 - $920 million
Diluted EPS
$2.40- $2.55
$2.40 - $3.00

Our updated outlook for the year reflects:
•An unfavorable currency exchange rate impact on net sales and operating margin, as the strengthening of the U.S. dollar continued to weigh on our reported top line
6

performance. We now expect that net sales will be negatively impacted by around $20 million for fiscal 2024.
•An operating margin in the range of 8.0% to 8.8% (previously 8.0% to 9.0%), reflecting lower than previously anticipated sales levels and pressures from the strengthening of the U.S. dollar.
•An annual effective tax rate of approximately 43% to 44% (previously 38% to 40%), due to unfavorable change in the mix of taxable income by market.
•An annualized diluted share count of 19.2 million (previously 19.3 million)

We anticipate a continued challenging operating environment across many of our markets in the back half of the year. We believe the previously outlined strategic initiatives coupled with increased efforts to engage with our Associate leaders, including through events and promotional activity, will help to support our business and counter the difficult operating environment. Overall, we remain committed to investing in our strategies to create long-term value for our stakeholders, and are confident in the long-term prospects for our business.

Jim Brown
President and CEO

Douglas Hekking
CFO

7


Safe Harbor
This Management Commentary contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including: global economic conditions generally, including continued inflationary pressure around the world and negative impact on our operating costs, consumer demand and consumer behavior in general; reliance upon our network of independent Associates; risk associated with governmental regulation of our products, manufacturing and direct selling business model in the United States, China and other key markets; potential negative effects of deteriorating foreign and/or trade relations between or among the United States, China and other key markets; potential negative effects from geopolitical relations and conflicts around the world, including the Russia-Ukraine conflict and the conflict in Israel; compliance with data privacy and security laws and regulations in our markets around the world; potential negative effects of material breaches of our information technology systems to the extent we experience a material breach; material failures of our information technology systems; adverse publicity risks globally; risks associated with commencing operations in India and future international expansion and operations; uncertainty relating to the fluctuation in U.S. and other international currencies; and the potential for a resurgence of COVID-19, or another pandemic, in any of our markets in the future and any related impact on consumer health, domestic and world economies, including any negative impact on discretionary spending, consumer demand, and consumer behavior in general. The contents of this Management Commentary should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this Management Commentary set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-looking statement after the date hereof or to conform such statements to actual results or changes in the Company’s expectations, except as required by law.

8

Non-GAAP Financial Measures
The Company prepares its financial statements using U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”). Constant currency net sales, earnings, EPS and other currency-related financial information (collectively, “Financial Results”) are non-GAAP financial measures that remove the impact of fluctuations in foreign-currency exchange rates (“FX”) and help facilitate period-to-period comparisons of the Company’s Financial Results that we believe provide investors an additional perspective on trends and underlying business results. Constant currency Financial Results are calculated by translating the current period's Financial Results at the same average exchange rates in effect during the applicable prior-year period and then comparing this amount to the prior-year period's Financial Results.

Investor contact:Andrew Masuda
Investor Relations
(801) 954-7210

investor.relations@usanainc.com
Media contact:Amy Haran
Public Relations
801-954-7280

9
 EX-101.SCH 4 usna-20240723.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 usna-20240723_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 usna-20240723_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 usanacorplogoresized1.jpg begin 644 usanacorplogoresized1.jpg MB5!.1PT*&@H -24A$4@ !/( &E" 8 !P3=C= 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end GRAPHIC 8 usanacorplogoresizeda.jpg begin 644 usanacorplogoresizeda.jpg MB5!.1PT*&@H -24A$4@ !/( &E" 8 !P3=C= 7-21T( KLX< MZ0 1G04U! "QCPO\804 )<$A9

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end XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.2
Cover
Jul. 23, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 23, 2024
Entity Registrant Name USANA HEALTH SCIENCES, INC.
Entity Incorporation, State or Country Code UT
Entity File Number 001-35024
Entity Tax Identification Number 87-0500306
Entity Address, Address Line One 3838 West Parkway Boulevard
Entity Address, City or Town Salt Lake City
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84120
City Area Code 801
Local Phone Number 954-7100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol USNA
Security Exchange Name NYSE
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0000896264

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.usana.com/role/Cover Cover Cover 1 false false All Reports Book All Reports usna-20240723.htm usna-20240723.xsd usna-20240723_lab.xml usna-20240723_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "usna-20240723.htm": { "nsprefix": "usna", "nsuri": "http://www.usana.com/20240723", "dts": { "inline": { "local": [ "usna-20240723.htm" ] }, "schema": { "local": [ "usna-20240723.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "usna-20240723_lab.xml" ] }, "presentationLink": { "local": [ "usna-20240723_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.usana.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "usna-20240723.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "usna-20240723.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.usana.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0000896264-24-000180-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000896264-24-000180-xbrl.zip M4$L#!!0 ( &*!]UAYXO6)F"0 ,%O @ ? <3(R,#(T96%R;FEN9W-R M96QE87-E97@Y.3$Q+FAT;>U]:WO;MK+N]_,K<'*KLP^EBA=)9-+F>11':=VF M=FHYJ[OGRWX@$K)84X06+W:T?OV> 4A)MF59=U$4\B&V>0&!F7<&,X,!YJ=^ M,@@^_-1GU/OP?W[ZOY4*^<3==,#"A+@1HPGS2!K[X37YRV/Q#:E4LJ=.^7 4 M^=?]A!@UPR)_\>C&OZ7R?N(G ?N0M_/3C_+OGWX4'_FIR[W1AY\\_Y;XWL\O M?-=T=$:[ML,\U[*;AEVSK%K/['F>Y7B6:?Z/_@)>ARYAWY,*#?SK\)T+?6$1W.[Q,(%N1-"L_%6V M_N@;L][U!]>$!LG/+]*8AM3ET3#@USQBL?\?YNG5?X;7+T@: MP^_O!S2ZAA%U>9+PP;LZ#.B618GOTB#K@.B+O)V-U:CIP^^S2+/$D!=X*[_O M\H!'[U[6Q+_W>*?2HP,_&+W[X5F$5^3SZ(@W^G M6S J\>==QC=H)_!#EO-1;UK O&^=UGF+_,J R'W2<7T6NM#X)1OR*(E)A[D\ M],B?*8V@BQ)ZERQ.@R1^-+(E1_U/&B=^;[3Q81L+#;O3^G)%OK1^;Y/3LZN_ M-?);&HR(86IRB'G_M]LS:V;/3CY^ZYR=MSL=\M?99?OMFY>VH1OO9[))(V>A M6R4GYW]WVF]>UNWWY%OGO/66)-RC(T+#D*?PF$=Z?DA#UZ? M?@R8)[%D\[\S-K/0@[=^2T/VYJ7>J+TW'$F7ZO)\G0V'F935>Y;3]+;(\]_9 MB'P>D^+-2Q,(=C%D$4U0WSX%Z[R70^IY\%PE8+WDG=F +XI!^T"K,'E7T>UA MLG4LST8,0L1HO-\?:-_?HXUN5@4M.O=!%3+H%0W@FWA+X/"2@ M?.,TAFNF/;[FI1&RY4\#H6<^#3W%E_7XXOE!BE9'^VN'W%%@0JU:MPC\XO+! MD$9PY\X'G0.7;>1K#[/?H7<=XZEVS M6JN]?2R2A5+Y=31-)5"M*;7_E44P^4'#+IO1QX1V Y9WLLLCCT45Z&M AS%[ ME__RWO/C84!'[_Q0?%&\M(I)Z32K=:>!%G0"%$N\_,.9<5T5QO6/B??X'LS% M(']/WJY5]2?OS6M6;U0;YN:;K3>JX&0LU.R/@A*2&D#O&&3BYQ?.V(;O4O?F M.@*SQJMD$')K+NUUWV>\DB(U!)SQP/<(BG)^*Y*PF'DOX<.'=S(A?6<,OQ,] M5U_3]OI#]DK.[MZ<%2[8*0]%WX7_^-"2>9*NYHL'4)]#ON5(A T5BD#GH#T[ MJ#WO4:4 Q'A*-6YS$A(4F3; 'CCFZY!FD MD*B0N'LD-E^3F/T[!?* 4Q",%/ 4\'8#O,8L%:B@J*"X>RB^JH_#.W]?_$T^ M_S?Q!T/J)AKA$:D8KS>*Q'*XD9\F83?E2&8Q-A$P5A[D4:D.TU$>I +>/H"W M3<.]''-4RTW\6T9.TQCZP"(5\MZLWF]F0FH MB)]0$V#!X%Q?;/[[42Q*K[,VO\WA31(Q:N\?I*/P<4)6GJLFTH6Z+.!WA*<1 M8=^'S$W@$1[&FFA#?T]B"J#\S1^0CQ&_"S7R%3- $4,B<>&T[[,>:7]G;BJF MQHM>SW=9-"-]I;!4N@BO.1)E0-V((\7XP'?)$(89I_ ?\4. !0@<#0CO"3K= ML!$\'=VP!%-Y "YARC!Y0_KX(@B5@GE XB$+$6=58 ML?!:?@,;IET_\),1MD63),+&D,CP#+UF)(1AN[GI(6X\F2,TG4\\Y+&/+'T7 ML8 BDY[,,,Y46&WR"NV"4@*W_-$KSZ0>R__[T4097;-*%\9]4Z$]P.([&MS1 M47S_\\\E0C^?[KP?'%VS$ 6+93E$ XZIXND N,X!"REF-)"DSV(VQ7$-9(_T M*4C,@'IL#+ XP8:N 7_PZ#0RNIBY#H@D_%:V1H8T3D@/1I")-S3IAVZ0(N#( MB?\6A3R)4C>1>678B,L' !V1JY,P.M#@,7A.CH6%^5,]#B C/ 01X!Z\#\V& M_%9H!?$&O (? E[&^1NLUQ,IS0#;#*IX55(C8# ^@*O(=*,A:<4QAQXDK-+S M(Q@!'<)GJ-O'IF_?H@JB0F;@&]#<&?Q.-8'U$[Q[2X-4JK !1]654\4#^@5\ M*'+]*1KI %\6'Y(6.H?)&085)GT!C3L_"$ SDSZ/DYS,+6 >3/IQEE_;3B/0 MZ.24A[ZT'[5/(FXL"= M!$$TX-@[ !T8+* 0*>(WXNEUGZ>):#5B XIV273O,]D$=$"I<)<@N6*@69J0 M2!Q7J7 J%:XDJ7"MV*?D*W5]L/$RL*M,.)4)-R\33F_J*A/N*+UIW5#K& IX M>P">HS+A%!(+@41;9<(IX.T!>';M-7K2[O3.E?$>-[6LJY9U%\6WV7#4LNZQ M:8]-+>NJE5N%V&)O.7"VBH121OTZ:;$O8L4WPM7RD*J0 MJ0J9S@V9Z@T5,CW*:4RO%VCRLD%@,)#IJ#X(*5JT&::->4\&J M8U,8GP.:%&BF4M$J!=EMS7$JFI+'#'B4] F&I50H1852YH52)J=L*JO@J%2L M8:I(B@+>/D)X*OM,0;$84-QF]EDY+"852GD"TI:A(BE'IR]TNT@VDXJD*,CN M+._G6",I'9XF?88;R:>3?%141455YD55S+J*JARENE7Y*0IX^YKG55!%(;$ M2#144$4%55:#=+.I@BI'IR\:ZHA,%7 I#9S_G[Z%(S+S@97RS,+\N56*MZN# MPM1!88<95QR?5(@'-V;G%*KSPE1L\?G8HF6HV.(Q6A9X^+8*Z"C<[0-W*K2H MD%@ )"[H6RG@*>!M%'B&.BU,!;@W@6]''19V=,I#U8!2 >X2P5EL)]Y-$:AM M5J40A44^TH"&+B.=/F.RCE"GCV4[+MDPC=P^C1EIR5(IH\5ZO$V.B!Y?];&< MR0!D:T3RHCH>>66/:REC,9QQ$2N7QGW2P]I5GBQQ$]\O=R4K)WG0 I84R:^* M0BBO3-.8;E0TA<^+7X#]_BV6*L$*67T_R N4X#<\UH7!1XQA3:=);ST0VI G M\."8MG@Y1H+'>?^FNE$EK1B-KM_2D+UYJ3=J[PU'$T5$-/%8WFZ?>K)"SG=_ M ,0(1N158]+S2;=243T%WY0^;"(_?:\_:=+GD?\?4!Z0-NQ@:TA"&-D$TQ&6)5,,$9+H=">CPB M/3G.43Y.C= 8;@2 [:+4D*E53=M:96G(-*K&%M9PMMEL>9:&9MD)T,)B2Y,[ M]*M$%:7%I'TAF_(1[7OBWQS:+T;B12S!U?F^B64_R=U]L.^2W?I80>P2Z]9M MQ"?>]A+I_FCU-0)B\32>0:P=0WME!;(/LIU.AZB66CQ=7B@/$&NS2W._LNLU M4@$KVGY\&,8JTOF,@):.;LZ,0T0V(*@S0P7SHP7E$>1//B9H>:3]M;,!Z2T, M*?=J5#V!8J-J"1@;U7I]V=#L>H1=6CL!U@F_"\1X[C#D 50 MUA^*Z15\3_15QZ&P&=7#I8>*5RB)4]=E<=Q+@WL57^$=GWMY.5E9\3<+@6C9 M)Y(^#>]]FDU_9 MS0UT5LMJEG_V0QJ*6LCCFN49/5H 0=G_8"3#,7$2L? :?I-%DF61VF_53I5X MZ&E'64EO#_Z\"^]HY(W+AV,=91"C_H. P(28TAF?%2+:6/W;K>/H#Z!=1MUQ M/71/R\F950M&DW=<,3J+> @W+X^$)!R>Z07,340D!!1$!2V]Q\#3'A:K%T$4 M.OGTN,ZV^-SX=1;>^A$/LR+1$8]CH'XXRJNZ9Q7=-=*'H5>CTFP)_2[:$#45HX T=230O-^>,MD46BL3#\N&.Z' %HA(7G44M1G%EI2,B9.LC+<$H?00:#; M &/$5?"U(]+- L;'E:%=U*KRL0C;RQ!OC'P>E_&^%[W&E7L:]S7R'Q9Q$9Z6 M0 -U/D8,H&=2HUY,M^/8^6%4V99:AH99M7*,NN)/&HU M;NIE&@8-#B(/89R MR<@I:( G@3QE5?P#TXS?&^W>AI 1;HS^II&HR^Z'0AR%0N-RPOS6:9VWD$-Z M\WT\2Z4, ]0D, =*73&;1%Y&(@WU@MLG?1J3+F,A 8$4LV@XO>8P_MP=ZX*\ M,G+RS")=K[=% O639"A"X&]>6DWYGQ]54VB25ET^V-/ZH>C:VZE5ES.ADX&9 MET(;S!I MIC!I)=RC$S;1, 0#R95-"OW@9YV)D;-_,2]D,;R@D=]2L)UP=4%,NS0ANBY( M6ZN1UA^D#5]A44B01E6R&\+.%O2S"C@)[F/<%),:)I!NA80QJ)I1*!BVB&*D]2ST\ M +*6N0.@3Y ]8,6BD8*"(,V>&&Q]% I@&@C%\IIY_MZQ117ZUB>IHW+F;WQ:&(PN0778Y)*^4,W2)H7X"\) MP1Q*-TXX;OC($'P;,*+1Z#S)G *D469ZO*WBO/T@ WOL+FGCQ5,-PT72>Q+S M9?YL15B@\,5))Z>GTA-<#)5F-KISV?&>&KA#D7)TT.M(LL%(V1L%R$ (IT;)+,X^;@K2&'0/VXJV8;Z)0+0!M*V MF4YBD /^8=9X8#3",Z<#4/:W #X@ZP/Z @NDAS7M7=/A,/!=X<,!+'E4$:ON M&65Q>.CEYR06[_CPL0%".9^#'KTWJX/E57&M+GCLA%P$XKCCE ),EB0%\C!M9>!!(P3B6&ER.>7O>1 MP,+^!Y\>[G=0#T W3F'*]:A&6BFZ_8$/OR*9_C]#Q]W3R*_H(O[.LQA7"+=_ MHZ 6-')%_3O\*_]D$%#8N"XNHR8$R* MAL9^[;Z[N[N)E;=Q%5#*^,LZ.^0+IQL[M,?(KS3J@BM8?.5XA7.;B%3#!"XC M"1@S$@$G$#0,9%,6 BJ5.09H[ M'@72*LE7/Z8CS$">J6Q8#.]JPIM+<=7$ ^\ME.^.KW59G]Z"[8*4R;H&0W#> M(_=]$?I-AUG#8'_#QV^0#I@M/F0B97QJ"LM>!!H1FE_T9/SA&DSC2(39!>>N MTR#3V#+.GL^4VM1,+!:1PGRZ!#.U +)AJ/0S*YX&=+I &HV>XYC#@ MF5FYP3X)+%\S/N1@E.!*Y]2W,W;VP(05AO1]I$RC#"]>IN!MT\JWFPBPR\8O MYF;NY (0]BR.*,O@@-9O!@C!4(\F%*W>6PKV/+X<2Y$=D8#>R4Y-V"SL[JGU ME$>]7(0IN6@3G%U<$.(?*KJC"?$(9U9+9K%U$"QBPE23&S^9%*-^V+:ZC(9 M; /W6>QS9Y"T;%P2& M20&7$U$8>GX@4M#''YJ:=\4Q+?GKNH +QGMBO=/C8N^$B"LD]$9NG> @3]>9\'&96R]O/-D=(FS0 MAU] ',K54Y1FS%/HWZ,=?VABP/.2$&-/4H\?E1BWI+&5; V] ML8\M@/?9/5XSF^\Q%:#+)W9-?TNVZV.#<@W+QO6 M>Q&@@,EQ>B6JP&KA#X;6T,HZ =7"8(1..0T+,J)E^__4OZ_"Z)Q:<][_^$1F MY*;&-RUN=DWI\UEI24]$#'WOYQ>^:SHZHUW;89YKV4A#RZKUS)[G68YGF>;_ M6"_FAZ?VM1_,J(U#][^V6U^N?B6=T[/V^6F[HY&S\],J:9U_(IUO'SMGG\Y: MEV?MSB*QMBT-IK;08$XOSC^USSOM3^ AG7AK[)EMU&K.D9]\Z>Y-JLU:[4MN_/O-59L=4^=;:R^O7BR0^/9 M':G.HT?W?73LLR(IYKX_LSS^-I[&O) 2\K0 I?AXJ:3'8S-FCFVFV!0/6E9-,TUS+K)VKY]*0EI3,XU&D4B[G&A**CL% ME]%?Q"[48<1[?K* B*XQYQ4/87K3T.KF?(@59EXX!GXXEF8WB\>/)?W0$LW@ M%Y.MZ]^'+(S9@], U\#P7AY=18/7"LZC<48DIAMA8M1M68TM!XRMIEXDBZ T MI-5KAF;:M2+1MHRRVI%IQ5J>MB=3#;V!'_KB' V0W7**;L,"8[Y>)'B5A[2V M5G.4G[1E*E_QY-X15+D]='0^4]W2&L_ 3?E,N_1A:YJE?*8"<:2='[4NMM%, M-D<BQSMN>QJ)R6RRO6S&?L7A6C MV"4W++UX(8JR!R+& ,&J:45,*H3#L:&BVT@A[<*>7 MT@ '""Q':ZI,HBU1MJ[;1:+L"A9\L^#RB3O?\D/)U>:WP]ZT) YH+:M5ZT5*P%1SV"0?[T)=: MBJX"LS+C2@D69PB@! N5CJ/@H)3@SCR=8CY:(L?D+_$'%A_,*L)-.RH6N+#;."C< M6O"@\*4[N]C)[IL[0GO.5%[ @YY;6*8,A6"%$[/+3Y1/S&6B/JI9T\C,P[ / M,IKPQ*@[G>G9:6/+Z9ML M;WA+ RR5B6,DQXY)WKN\/>JC[; Y;';BXM?Z7:!&GA0JX]?[=:D;:(E)\?3:UI[?/(S1+% M4[Y&>$)F,A*S+;KWPP%(>HG/C'&:6L-6\^Q62.MHMEXTX[?0TO<+Y]Z='P3E M%#6] 7YF4XG:=K85ZL]4U%.B]O"(0AI>^[A4+!]8CT&[J.'QYF4.H*CVYKN%*J$3WE(:VJ&?;"6Y3@+<==DDP<-2IG[ MKP?9CZ7"1[VF.7:A3KTI#VDMS7[F L5/)T7/)T]Y:T?F"O<1%_J][Y/;E[.JL MW9$;1JXN3G__]>++I_9EYP?2_O/;V=7?AYPY61#BST]0#7S:]0,_F9=%= "T M/HS M<2/F^0FID+C/HX0D+!J4,Z3ZYJ5MZ,;[@FF/:VK.#HZ_*F]L=34I+%4VI%XS-5L5A"\./W1;LZWYY[RJ M[-15<@=*/]5:6J->M$V<9:%LO5ZT-7E?0NRR_[.DUK=%0>R*W M0EI#T^O;]R!*\0)R>=]7R8YH>[B4?D3Y)>M1H-@2MD1VTUIDV$?NDT)N MN9&[<-[47I#[Q-F^6<\V=PCGTV]MC2^BQ7<^S"^^^PRGFL"I_YK.1L<>_%A M.R,AK/QOC:JS<8V#J/>1E\5715=G:JNK]H? M1=?Y=%VLU2?BYLXZ<7-#?[BXGTT \SVL@A^"_F=*(^@3:8?>4C5\YBT$1/QN M7H2V^$0Y[=/PFI%>Q =D&/D\0NMBQ&BD")2=L,4B[!5Q!:$45::WR;@CX@^& MU$T(#Q$W,0TVMEWFX$GT.H<,$(9]QW )]#U+>7-'>%72;E;UA8?:?*U=?,Z2 MF5K%)VU>VH,L6-=CC?H.921>,"*ZH-V6JANJ1?:E-K_%/B5?J>OW%JJAN9%: M)<5IY" [?9 C5]_;3?V=P]@&\TO$*#I#IWT_I&J_;7&&H.MUK:ZK/.+M'(94 MW2IA]S&FUVO8<$K.]YE6:VM-:_N[QXY4SN>?]Z_D7,GYCH9P@H=?FHVW2L0W M3-;:NG-YX=#^^A%(E(P?AHR;6LVN*Q'?,%6;U37-H\)A_8&$ES&PT.%ITF+.F-8Q]GE*]MI8H%3_L6G7^,O#6F%$"@[542- =4VOH2C*+P@];?R8NI"3S M2) [I#F.$^:SDHH=VENZ\^LSJS!C<*9JYOV6'M-.+#IP^M.>B8C65HAK5FT$:%PYYP8M8-'!=O3&J5 MQ<+CDE4:ZU8$QE;+DN7CZHFAF9:IUEHV;?&KC9LEY*IC*4'9N*"4/-U[0;=+ M%8@YW@(QAFYH=J,LI8V>CB%M'L7%XR7\_XQ&VQ,G#\V\5@KPB!2@:3];/5$I M0*4 E0)4"K"4"O#$J&NF^6081NF^P]!]N'MY_HD>6^-DX:1Y$P=]*=UW#+JO MKAE/9_LKU7<@JL]^9G/!T6J^;937/;A*KN:+#]NIY*KJM>ZUH&CK].KL7VW2 MZG0N3L]:5^V.&$)V]>ME^W/[\K+]B9Q^ZUQ=_-&^/*C2K@=0*W6W54]MJZJ; M%@K>LE5/#:L*.F'C%03U1M4R-E_R4H=AKM:JZNS>.FLO4TGR@<%FK9T%62S] M)9,D13UXTHIC[OHT@8:[(W+)KF'>SW7,1KO5J-87Z-<,MF/ >P:E4E=#;$!F?**97 MCHQR(5[3VZW?O*S;C[S8S<*EB(T<9*>W7^6L636;!0?OW#IGRPEFH0)+8G - M6X,/''/NH2"#67]FY])AK8Z*,6TD^_I 8=W4%:P1UN6J8C4#UJ6;*Q;6YB6EJ'0@_ K .3TB5;"ZG MM6O;"PPIV52RN?5ME&HCUM%N%U*=51NQ=KL1ZVO$>BR*F$=.TQ@ZRZ+#WI%E MK+\C:UD3J&#;9':^+^O Z;6QW5ESZ7#4)%4[M8JRU4CMU%([M8YKIY9NJW1Y ML6.MH;9JE6F-1K=K"M>(Z]*GY99NTCFBO5J&2A! ,CAEWT]Y7'./0G6&ZI)O M0"S=S%/RG5JZI>02=Y*JV:9,LXVN]A\*1T?M"U;[M)Y;""@>CPU#[3=9A$YV M[=CWFZA]6O?E9GLIIF62FZ;SS/[ETLN-VJ>UAT?+L79]+/NTZLHQEML6RKZA MY;@\XWI#P5ID_)<]X*/V::UZF-H65BK47I Y9O81[P51LKFD;#I*-I5L[G " MW=X^K7_2./%[H]T/M2FR_?6WTP5U:,2('WILR. _Z(WGQTGD=].$1R(GFZ<1 M&4;<2]TD)G=]3F@0"H2W9KN$(&_(Q;3@%679]>A<-EX.W.WSFS& M(@A#S!&P,_2:#5A",961 @0>&/,728X$[>^G/\G]7-C0*A M*G.529KX 9 0FICQ3>SN=40'\#Y-X-LQZ3(6$G\P#-@ Q1STXY")I1D:C"D% MCPYH=,.2IY%4C#J7/W:Y-X(?_600?/A?4$L#!!0 ( &*!]UB$#/@(3A\ M %88 0 > <3(R,#(T;6%N86=E;65N=&-O;6UE;G1AV<1>*S/9>=K3!!HD1B":@PLESJ_?KZJ[ M 9 B)5&6+,I&'F*; !K5=:_JJL+WTVP6O?E^JJ3_YC^^_\]F4_RHO7RFXDQX MB9*9\D6>AO%$_.&K]$(TF_:NMWJ^3,+)-!/==K!",^YWC?J^MQBJ0XUYP/#X: M#(^&P^#_.B_P*&XWSZ39,E)_>C$+X^94T?M/AMUY=GH9^MGTI--N'[Q8O4\F M$]PZUEFF9R?M5@?W9NHJ:\HHG,0G'N!3"1X)=)P!M 2O,G\U;[S^WI7U.NTM MRX6SB9!1]J<7>2ICZ>ED'NF)3E0:_EOYLO7/^>2%2!/OYNOFC7:71\/YU>GJ MVP=X^4(E6>C)R + L)C+%B7==F=^M1&#UW:R'0TW(]0^Y^[P=*23DY=M_N^4 MKC0#.0NCYB#SW\[/?CL3?U; \U2<>Z&*/94VQ+O8:WWSLG/4/MV?_PLA_I)' M2]'M-5A<[HS=-M'8_ICIN?WE\1#.*YZ$&;C)NYD$+&G_TS72_RN8>*)8:;S5 M,_I3)DMQ;9&O:Q@;^JI?@YC&7LA3(2W[SLC4[%^[E* M9$8J[Z-*\RA+MU)K+GT?]S4C%60GO2.G"\+8!P9.FIW19Y"-_L9]??-RU.T> MG3K(/S\(IRNXZ?1:C(MSY>G8%__*90(]*6(%J&2$=UZJ1(E7W4Y/ )(HU+& M8DOS%+_U1L5O?IX060S7]5J[Z*C3FE:?1BL_C')R!G[Z<"XN)0C3;@WZ G_Q M]&PN$URY#*&'\?/H>)U0US5!3:D'I-1;HD"\%/G1UAE+L%1D,JHY3TAU+/0 M$V"F-,WQ/UHS54 8.%@'O,(%C#0P=*$RTC8Q3',.]@4SA>![+Z/?4D0:B4CG M*B;Q:(G?-9X(X898".5\GNAY$D(^P(]QCL4]Z9/'2"_!M9FV &(?84Q^?+@@ M4=()@S"F& @0-F"IX-BG&H\%BK1>H&"[JBM8W;UAC ^ UZ1ZI$ !SH),4-/BB20;Z# M(/3@N!30&]G'O[!=H$UF64)XB\$6[DUFYQ,5D^^CQ%RG(6' /CK3Y-/EL^KF M[*XV*/?]X]S?=$;6*A#SY*IR(@;B<,\I,R8NE(IXH4+_\_4<2/J4@TULV,K?RW2K3PU3@S*K+7 MZQ8Z$]Q ZX*1IV$J5"S'1 ;X0P1Y$*FK*JPA3&X-F,9R@C&"40K MC$%*:?@YFR8ZGTRA]GFEN9(7AO(9_\YL2!?X.>$5@6B\->8 MT,01V+>IY1:C^OV$V0:;Q'X);+ Y#!8C>I+HRPR;^D.)J5PH"ZWRJS)?P@VG M0J9.!Q0 :=QF8)?8**3/,2((!<&-![+QGK!"HR?P"-X$0'GGE !9 O*"=L'=A ) M5:0N4A!+B!=37,;B+$VU1WJH&80)=L":27I36GIQ2/K!\BBTET8PZX>RP11Z MC:N6U,S"6LQSN,A01QZ 86']E0.8,_R"?X(B*MU1.M=R#IQ9<<0]253$7+0U MU^+,5_F('$-&X&SLDIZY+1EC_C]-RB!LHIICD..B*0/PP8F,+N4R?;%3NNCV M!-#3**[WCH\:5O^#](8=B)?S./2L8?45G/",M'1J9&NL5 P1T,E$QI14,ORD M8])E,!O$+FOB8)4-_56$J1$#/$=QEXIPO]7\B8(&RF-?F\J, MH$AAXR/%.R8#NV 'E\0?+T\4O(98X9U&N+#=2YFP\%!0HN*4D2/F4,=6AGJ' M M1)Y<3L1;+SL%#+ JAR.]836 <,JDI6H>(W06FS1Q/'9! 9C61=04N'@A8HY2>E:$!X10/@=V M"HZ.\^A<1$<^H[$O4*Q,67B.V)VJ+%!&31S30)1G-4$?C* ?$KT(*7:TJM*O M&+S0!L$E98V'R[G^TM^&",9DT&>*792T8461[#%BBW!>"^ #FK09M-I"%>'7 MBK/#>0DB"5$-?O54D&/(Y CR*&IF@&[%>=I F3T,X,$14 YQ-N5PG-VI,:)( MG6;.'I]!4< =3NTISD\YK+P2;\F]BQDST#__C643AZP M)#F)G!Q!L)>3HJE8#Q%)_#2U/D$^GR2(Z1!;G1>QJN%_83);P#SS/4-9C9!-&@<6+\PHD<:$@G/.KW)&S+S0;8U ,>ZH"407Z@:[MG_$>Y]OT1\N;KZ> M53('0I40! X63$"*OUE4L_,.NDU5Y%?3&@N94%*Z,"^@NO'K0BD^2&.F$M!, MQ^2H4_[,+CBW6I!\1';1%1#,,H4@!W#FLS(=N.8ERE587:ZB.<[#B-4C^8AX M <7E'C&.2X"0=-LWE&AINJ4L8#:%.9;>!9Z* I>CX?P^O=ZQ+HN^,Z(VT50D M)CGC&2G$;']7(:G,>K* !9Y$2)I>)[*H9'$H_*YO1 MYIQ+2[Q?N=]I@D*]ED&VFN$VRN\XU.$7:=D9G/2O)I6KF:VKJ(0CF(F<&X /\R5S MB^M"@X8Q!:DVE+S7N8W]&);N5Y^?(FTQ4Y)RI_ N*JG>U5Q.Z/2QD1^C-<=+]A.ZAQ6UHR:QU3DL/!4"[IN7_>$I'B-'B"RA M,&)KS.:&/6"1XU/1/12NS(T<)34Q:M)<[!5O,#$G0:Z3I4FDI\5M_4,ZYHEC M%:U?H:<&A^6O14J(/>M$&?<:%/$HG_X,:II<4599U_2A/++=\0@Z8T^HT- ) M>*V)?41RGJH3]Y=3/TSA@RQ/PIBAX8?N4ZMX/&P-CH](Y67 9N:[%UMMV&)M M^%WF7[_6[;?:W=[6R]C.UFLW+=LY:AWU'G[9P5&KW>_?:=GO&!,&&\ W9#K^ MTXOCHCB4G$)(+51GT[*7U_9D,#ZUM#)QXSRS9Y6D MVEQ+#,QFN<;UZ]8B/1 MD^[\2FPLHETGKZ'L$]6&(NQCV+E^>;V,;RM>>R_66/T&].V&(EIHKQ#T&VPQ MUW.L8&4/D/'$I<;7##MCJUJ9N.9_?0K:'DX$/P&E^WFDQ&A_VOP;0-BUC=NX(C[JQ='Y+8P['X_!GN856YBTYH9]X091P=< )=)ZMC)DP2. MZK+FSIH[]X,[7PV*FK9_O/^'^/E_;=%F0R ,;'8/:NZLN?/IN'-X(%+UK]QD M6Z)ES8PU,SX=,QYM,N2/QIY?1AC[8]G+4@>R-S/>@/)1W+551[!?O:[I'=<1 M;,V,^\*,C^F&?1EV[LR<$[YUY06UL;N#L>L?C1IX0VWNOGH-TW\8:^=FI6RD M_\,8L7U\16U$GP&+#^YF0[_CP_F[#3:J-A]M1?BCES/\8+MIS[F/EJHUSJ=4 MAO)1S?/$FU)KSYGI=UQN+6Y805F[10SU1"7E?ZBB?]@7K\K1)E2F6LR=*5N* M;VDFASCXJV6S/(.CVDE,'>2TG"F.P5_ ).&"*D&SE,H,(U?_2>^A9N1FD"C5 M$CO-[-C#805G7%/YESQ69@13]]B,7FIP;6B$].1<V.WAL&FNHCC71//W @;IT4P)H1:H()CY?!XMJ;X)8"5A>N$( M:U[ D%2K]/@%X3@O6K:K[9V*2].H>!8\Q2WF<8Z[;0GQ[>U4SX,[((8^3%BL MJ3._T"-<6$O*95-)>DML9RFJ0Y>^Z>6^"F<@"@U%.2JEL!0Q;IOB=4V.+S-O M7 $CSZ9@SW]SE=O#CTKY:LISUQV]O2O/??Q20,.Z8,9WII/Y/ -O$[X5(&O_.AXTSQ9TG+"=TUXLWOR0ZY0+B"7=[NB:U81OJ. UI_$1(QBQ( M],QTUB2A3HS.AG8;=5J= Q+<8@I2ZXF<-R8)-9T4FX ]B$6$C9&^H/+C0AKN#_BR1HTE(*,UI7R MJ9,FU!0BI-Q\P]7 9AA-B:/];_^XB67*=J-WY3"?DG4&=V.=?K'=.B/WK*E^;@8Q-,0O[&)'C((S M']H[Y)IVPDH%"XX;8,OOQ Z]=JM[0.U[DH8T$9I9JO:*/9P=+[9'0S2P#6A/ MO-$)N]RH' P#T6Z;-&6GR?NN:(3W-,M-.+-O4-80Y[_8)@6'V49%T%XA/"V< MH'6O>BVB 33D3!.,Y*1SWVJC5$W<#6?:[7S.*E#S5I/WJ_SBY<]<;_UN@PT$ MW4V?NR6#0)G<;R:O6,%7&)=45*_5/B@9MC<@C05?4B=VKA)+.B.>2_FMZG>X M!G?WAJWA 3=S5".:)V=DCD*23?LGF[EJ*TO^=@-5.H?B[32,)65K.L/3JK07 M$F+\;M?M4=QI.NL(@8$&VS:H_>2,8B82^,0U66/!()'E@!=C2VVS*J[9?@N YF%= MK@56 MH,E;>929(5:XLU@7L/='K?Z!&^*P60/T=S-":^'0(PY[7(\ZKOG<@^I,Y(_< M9 QYLNT'S)AU^TW=?O,5M-^L=-L;0:B[;^KNF_MVWW2&G;K[IC[I7.4=W?4#/CGC#CJ,VI=*_:F5\D%^N2S[KD\R%XOW=T M7)=\UMKFX4H^ZZK.FHN?7X/J\:-RQQ>9I3S/QTV3J;S#H*!K^/U:4?@+'P-\!2UM;;;Z: NSU20-/ M68!=%UH\OT*+6I_7^OQ1CNSJ:0-UZOFAV;T[:->IYUK!O'CS,W60[D_T4N>> M:S;^G':RSHVZ#*!.LBE_>*I.C-:)T7M/GF_7>=%:)5N5C-!_CSR+.H[^JIFQ M4]>^UNRYO^SYF+6O7X8G5J=Y[L'N_6Z=Y:GU"YF_T3[Y8G66IV;C)ZTP_%JS M/.6.[MU MPJ=.^#P\NP^'=<*GUB_F^WSU1T3J9- 7S.+_U7FBCX@\YFYO'2Y>Z6!%\\4;\YB9B\+#02-- UO)CH'PAC 5]3""B&QCJRKQ=^C(]_3XZ6)OCRT,Y MYV;09[1LB757P(R*#5,[--1\&(._A;&Z3DN<5QB$5K53+BN32\6E3.U<4( T M7O)(TC60S6L:XG)*+P+#3,MA(&9L\SJ Y2:/#\P$4S/V=2G\A#Y?0<-%UF87 MTSHE/Z^ B)VZ ;+<^F&'(M.@8?[4!JU6'9XM[2=F-GT8XHY#/9^%.)1%:\]% M%C@!*_ZJP1S$([2.+ZA0AAZB&H6;!*&QE=?,.IVC S/WNLI'=O!U?#MXQ3HC M \[@8/WUYD,MVP$8X/T_D'3'NTP/1T@HSKX/X/P>( IN(?1ZVGDUS4AL7/.\W$WX8 M!*&71QG+%&2,IA;'8 G/[6[#C.[M$K-W$K(YX?]9$3,PX]5?3YI1FU\O%W MELPW=(JQV,6<;3.A>N6=+?'.",8'[#.&T'VT7MJ^E"'>Q]%^J3Z;D7;PKF/;9:8$<=]JD48B .GE)Q[B*; MY!##=Z[8N%*EJ'@1)CJFCRLU^.L%$;W$.,#&RH8>7$J5IGE"FL69VG2CK=VN MK]8$_,[&]&E:G2$MT>/T.G?;PX?O=>ZWCH;;+]=#Y3\]>PTY M!"S&_/V4)Y".>K9\76WQB=46_6Y=;5'G/\N/*-?'V34O[@LO;BRVJ)FS9LXG M9\X['A35S%@SXZ,S8[<>+%]7 3TV[Q_7<^5K9?. <^7WL42GK@*J6=S-K[I7 M&= .GVE]6I5^V]?CMV8:]^F8-XS%6QE+?Z7^YV#CQ\O-F<;&(\-) L Z3W+J M\[0?F;ZM JH\@NX=M%;13MC]6QR2HWF>\7>7RX*1]L%MY4O# _K8NEROZ."J MDON=^5HV8%+:,^C>72M-5K?Y;L/FJE"49]VK >"-IV;=XD#[#[5284*G]>!2 M3X&(,1TG(I'+K7[J'5#3+$DD(>-72L$&"_-UZ5M#0#7 M:P%E?BH(W48XJ( C +[R9I7\VWV__!W$3?X+Z M?9Y%6E]\ZB>S'UT6J9CO+7VC/EY285X^]\VI9YBE:Q* K<6XDE(MG_N N]ED M]0OV2X>!AH 2#W0$]GL.W]]NMWJC_GV.2GO=5O<1YC<_YK)?SO>W-SFG6.%V MS_03"F,>2F_P%^OOIC?N%-Q7>.5I;.+O;ZK?!V=W68+TH^7ZIUCOC>F>%\=QT!F&6 ME$:O53FEV;5A\?; ?MMS%#R?[DLX_3Y/3 P-0:]&QY3WX-#8-@?M%!)W6H/U M9/J@OQ_)=-[TTR;3*:&\,9E^%HL\#N1")YQ**')WZLJ;D@LJ$I"IJ/F.U](= M90&X(0;G,TQJ"\M,\#?*AM#I-V?M6NTB;I%Y,W1FC;>PQ:1S>*WAJ>MOL_GDL)*BRUG>V-]"5:G+#0X5&85]KZ$ M9R?&ZGKG@\G?2MZ%J(R_KR;X*$MQY[;;>RJN^^#R0\LUITXH=-L;7HE.Z4@[7A).S" ./D!UO$\$ M%E@G<+K1=&[CI6,5A8J$CVL)"O111,%'P-"L &@2>E@*?AY;\93P/X]P]3+, MII7#9<@RO$[N=03 \*3,#03069IJ+Z2]14HB&DT;]%R4^V;.!I@/SBL B3.G MY*^/Y6@8?V*JHCD?+.=S4I^D>9:YPQX!W]+$V1+O$=X"P7S"G"@: M8(+G9[,P,]XSH,2&S4&E<:T=1DQ/I\>396#&P+YXYTPL9 1-1&Z,N5E>J*F. MS(X).,.^<1"2IBC'-+C'L6\^ST^+)=S6-O2 /B4;;SZ=_DLX$S\D^C+>$['Z M #?!8)JGTOST_G%/_Q\=OS]"3B*$AW]6%S2*8T^P_/;GZWB]2X+EJPD]AWL4 M>NY?2II(M)SLG/A9O2'9XY,XR?\@0\#,C//*.CBKLZ/VVX MZR>74<+ML%TP#S".Y$:[V0&P?9'/5D^1%P V,J5;-E32*9EY_4_%(7A1<[5] M+VYF$,R@CA;DF<3Y;&P&<25A>F$L;AY[*B&T$) 5R\ZY1S&)]+B80@1/ G_Z M++BIF*B8S>^RZ@Z4OD\8TS &\@* >1?WN;0!H>92)]@N@>!2#)4TV^IT!4^G MF9G(8 K.?!C[V+<.@_UMK*9R0065P(P%#5LX/@5ZHY!'BN5SNW"L,KS\@O! M7C\-2B).*?RTX0JU-C_8,I-]H>GE').X-$)H[>)J&.@1BEL)S%E?@\-$_/R M1.FYCD(^F:B\VY(SB$*Z;4>9+.25^'\BY$<:(M MR&!X$&+'/! 9RLTQ/V7*F\90F9.E2)ECY8G91./@8B"2-&:QB=$"U+*4FOB8G'6M>K!#X6>>^@ M/PSS!'E&&B$DFQY+&R]@2]#]!%4EO8Y'S;M*7;6T?$/,8- 21#FI4S=.BC-( M)8^NOL5F^4,GZ8YG2KJ1!R]9,R<31C#P]O;]W]_]V.P<-U@Z8K,PP(4V"CUB M3[$]BK.;-5K+ D]*LE!XA1Z;*AEETX;P]8R"%X^?,;K2:N$5-V:ULM;#IE&S;F!\A[3XRIPK_^">(Q<9@_ M./=(^I54I*8 Z])6CEJ(9%[ 7AIG3E';*(S8P"S.Z(:% %;)0Q1!&'$):O&B MBA'FA@%GB GP,"5N,YN\P2UPM>=;MJTR>MC&RQR7!R03S@N@HSY!@S1UP)&[ MKP781W!' T69AG$@91,KD=J>#_*%K6 )]C77WT#<2=&M9A%'J T7H(I#O>YW MX'Z#D();;:TOI9TZP]/4GA 826S0T9B:9[2]1/TK#Q-S( !M>3T/5T<2E4AB MM'>1Q.>.%G[3D G^A=!;= @<##\_I..0U9W/;I_P488/_W3DE.;27 M*K\>ML3;:U,FBE.Z1E%PWZ"2H8K!<_0@JI]9CUCG='FYA/W$DT__V_YIW79U=VYX!^[),J<*-7\!ZV0PB[!/> M+2C3G17#E%WK#AE;V[QBPBGJ4ENN./A6T6ZBY'50V+S)R,L-V:A5)@$_.V=G MZFH4,KOU;S?M1V;F;$W.8$(H2SI1Z_@%"8Q/6IV8+.?PC3T^9.'N--/Y9#%K MO:38H9B?H3G-,T[I6S_LVG.; -PQ(;I/32"?,#"O/VJUNW<;0;?3LL>MX6BG MR79KIM>B<6-UVPX%_AMOO:48=*V$3="?O=9PN!\UFIOM^#NK%(P7ZF6K55JW MX^H=U_N4N5[#[YY3G@I>."C2U_4R"F0\WK4[AR*XT&_.>QV M-E1[WATQ%=V_M;\N/WDY^Y8WKFH>4?@-A D"!Z-(#=UTCL' MIU6DX;YY>=0_S?$VQ-=>"Z9^>Y?9NAD9U'9D%S'Y55$J[&LP(K,EG1')G=I$ MOG =^8&3JK7YV)0G:7>:QGB,[M(J4.>8*K@[WIYC^FZL_27^F&:SZ,W_ U!+ M P04 " !B@?=8,.],;$,0 #\;0 $0 '5S;F$M,C R-# W,C,N:'1M M[3U;<]I(UN_S*WJ9W8U3A4 2=VRSY<$D82?!+N.IS.[+5DMJH-="(MV2@>_7 M?^=T2]PL;.QQ8F#'#PFHK^=^ZQ9G_YB-?7+/A.1AF?)H1*(1(U]#<N5:VW;)C6PY,8WMEL^*4!A6U[B@"F 'N0#9GCO#Y>6X419-FL3B=3@OX MI!"*8=$VS5*1!S*B@T.W^\>F1V;'2I79H\,R=RU M$?"], SO5R8O1H(&$G%,(Z :KETQS+I1LE;FR5[UL4ELTS!MP[+3269R'3'3 M4KIQJ_C[E\]]=\3&U-A 4-8(J]%H%&>(],74#_"RUA5;TZX>6^Y"@9'B QIP MTR75L>E3X-<<"XS?^KG6V8A1KW4V9A$E.-1@WV)^?YYKAT$$O&OP7U=_ M.\]%;!85U?:*K9]^^NDLXI'/6K$,J($L:];LTEE1/SPKZJF=T)NWSCQ^3V0T M]]EYSN-RXM-Y,P@#!AO@LR9V9$)_Y)[' O41VGL@0(*[>OU9=,,&YSG7 -H% M=(PS,=Z\ !'S4,P^^'28(YI*YSD@:W/ 9\PS!M1'KN'>>6Y@V%:N]>'B<[]S M5EQ;X1D+=@* ;]Z&%07UNX''9K^R^6)^.]J-K5\H-%BNL0"C9@ E0( MDQF$0( M1>SPIS3F?Q![RS$)OX]Y8(P8JO5FN3*)3J?IB 9CFAP"J.0%KJSWKZ!XMD#8ZHX[.T@Q,* ,EP0]^G$\F:Z8?35!RUOC/4 MH-,Q%4/8MA-&43ANXJ[![D7&&,R/@9=G@Z MH1[:[*9)+)@C7:"H(,^BG\9%%$X4(K:1:;$V=>^&(HP##Y$=BN;/ _5WFGPS MU=_I -@/=-.8^_/FNUL^!AW08U-R$XYI\"XOP>" >1-\H#M*_G^L:=FPO/HZ MU2BHP3R*: E*+!O1_UNO>]NY)/W;B]M.?YUMLJ%2\^X]6/U.^[>;[FVWTR<7 MO4O2^;W]Z:+WL4/:5U^^=/O][E7O>&#]>M'_U.U]O+WJY?K+]#(%]U)_ ^7-U\(;M[%&F@H'TM[4B ):D;OSYT(+:@Z(@I M?A ,#:KIIM.[)3>=ZZN;VT.$JYP)UW4L9$PAAHU"TF!X8,7('&",!8\XS-J9N2-PR!FY<". DUB-4OEX@$7/&*&Z89-01.0D_=ZA MX!LS&9'./:8N=#/SWC^"?.I4!,#$1L(L)[G&S#*&X+8O>F3SGCBAW,F5)IVG0D> M@KQSJO$XC?J%YPDF9?+?9YC/2D6DEFN5ZJ4Z^8K1QS45=U,Z)[^$L<_NJ?". MQX"_$&5M^'@E;L/IPK6IYUI]ZD?D,[UC!)NWX6BO,B5Y\L;;>E6J*&?L2ER# MW\E597='M[3QN%NZ5Q0[*H)=AT 1_]]\HJ.()-EJ@GDNP[S'HV5.$G@Q))@( MX$T^H3YA,^;&$;_'"!1L%)-Y J@@B(OWY'"!7286WDD2,9]-1F' 2*!/E]HBY=^J4&)V W0#9Q7#?"6?$87XX)7R@&C^ MG2%UXU?R]Y^K9;M2PYF&A$M@]H@%'O,P8R_Y./8C&K PEOZ<2/!)Y6"NQJ\- M"QT0;IIF$+!Y)3L%J&""T&">M@U"'S:"X]"N3$JI'VAQMBE\P"='R8>CI RO=#G[L 8C#\ E((HN@_3?;RP9!]"1T9 M)^ ]I+E5IJ!G5\B^5A=;$+UL%G3/HZ#[M6 H[7AJ3A7F4:.*J\$ 3<]3]*\< M#/T!2L-= ?-)^;?*GF&?..]WXP;=]QCYH2MES,2SN*)ZQ%Q18D;YQ-V-*Y*^ M.]>U]LT]6S%ZVD=B GRM2=8Q"24IB<\$>'B.BW00Q9C2ZQ5CK$;!K&0/>>Y4 ML*M:N?%'ZCH)OGTV *)/(B+!3'KZY&C2I"BUWO)(TAHGVJO:QBV>ST?.9-0= M$=>G4NZ0EC]^M BJD@3]^=@)_1.Y2ZWB::0(O<(Q(JR7'&50;,12E0^J;SKB M\&2I'Y]3X%H_NIV-M^_*@V]737I&7**MT-RR'27,"S>CEFNAHP(TZ$>A>Y2>^C$C$[S!,:*"O:"$^R=M=J!-HD:T%ED0IHZGG'H7/Q[IWU?_ M' )!4F%)G5)]^&RS4(/Z:[U&8S5 Q<%F_Q6*.RU."[_VZ0K^KB7>??-ONX&' MGCXCSIRX*A4)&[X#C<[4::.-W""7!/8.80+"-"2P\VDTPH!A@OE"*HG'!K"$ M.M6F,TAF)76)-])'^H1MB9S\_6>K6CM56:2T,U?GX29X'@X//NFHPW8,.V.N MK&.[BTDQ EF.6YFV\))S=DJT]HV G2W$>*U@\X?'WKI\EX+U44'5UD ]?=W3 M?"3L/CC1'#PB;%CERI1<_B"A/P*Y9#Y$J2"70:ABUE@RU0M(D!0/\,8S5W&L MOC:)F%9K^7-<7%UE1[8* #9H$>R>2Q@'TDX#%Q.)U'7QN"9VQEO/'A6>U 4# M;UO 7#JABX!Y58P+^\:\X;&%\GM\"7.WB[>US(NW^R+/V579;L3&Q"Z8-AHG M\_3AOS=,QGZD2OA7((5)_@UDB7Q8B%D[!+''AITMV(_WUQ2T5P%9NQ:1)\FI M?T9]T"5]EZL[ZGG2#=P".=$URKIMFZ>)LE??K%/4-DF#FB!Y_!Y\$1F#9J&@ M9/#<@P 51T&MT2 &KNJ.@JX7"HHD6 7%1NN!DX@X))\B]7!>Z+UX#_C@!&[ MH;?\>GKH53%[J]1[ JTOPQ1D5.,C&BG@$AR"WO9],@EE!'CRTO>3J/"E6 MO]" #G7F5^>\(RJ6R ]6I\.G5NU4DBESP%HPQ9MJS<5!$YDJ]+4=C$(?*04( M3]Y-0$"I^=JJ\ !&1:$ 5@#CX( ]$R'U7 I[#N\3%_1K*&""KV!*R%?FJ&7! MZBU/?N"#A:T!2X0,P8/%&SSR!*_QZ-T")18LL+&? KE=V3B8RE6,)AN&?V"4 MY%(YFX[@#*]VH.65:DL9R!HO$1PQ.LX#C+ !1L9XAFQ(/"[ ((*D\ #@_Q8# M,A9R#UPR94(6R 6L.EE4Y-2D,>6%Q"D%M#N9=WCY(I@;'']"P> >%0BGP M:611>A8 M*<;\X@+*%/P^(F/GOS"=YA1&?$X=[NN9U-P@,\ER6J:>AGCUU);V3#5KYM=A M7N.W54;3TH-RFWJ^:C%U'%-)Q.("S4(-KOJDVP/452QH8!*2J(,T&I&[$11! M6#FMH^76"YEJR2NU IHY1D4%0*",HP2K215&9>R.5A?GJ *^Q5QH5-RP8>SK M[A\NB6* 1'6M;B]K;QB,40XJA\OEP8!4+6^,I@M0EMPP 2^/NZ#!Z#WE/CIT M&>*YXPM5S$-U[&H%T]KNV*V2YI)+UP]EC"G9XU!BGH8(E90#-CLI#"_\725" M4P92#/^O"C>A441=5&XK(QJ R.3LVTX6YL6L5LIB-I&31F/@1+S MT[TAQR/\UWB$_Y;A0S_5A]J_2!V W=-A21BG,]#U1<:8!W@/IFE8]3<+.$Z\ MS,.X/V;Y=;Q4"Z4RXB%%[[&E#RQHL)]7OM_^O&Q67^4@0+U:L&JE[W3!\ZUJ M(0\$7A$KX2N\;?:,^W6+S,N!0W_)I"OX!"W/"PK-AUP#PS#M]0C^R@AY<-)O M!2N#P7?#BMZ<9R0_M:!E MID:7*>-==.G!Z9WMV#@\L[ =ED.U"MLA^M,H[(]1L,SR'MN$[PIZ6U7?KH%) M00E&#$4)+Y)?THCJU[NQ+JDRE-<* H[F'K&[63U(>Y'$(="&OB:/N0Y[^$^]EYQNHBSS@22U88,L,1 MC-X9= "K-JD_I7.)O/.CWR2^Q^^@V?)BZ.['WL7M;S<[ONQZ#_/GUQN5IZ2, MH_.RNQ;G,DYY>6@+71I+5;A6]2%5X-%U=0DDU1573+T[;$3]05JS5D8JZ8#6 M)L9JFIJ.QM$H% "<]YR:ZT&D,:[$*C\4KOJ:L6:O57>4]=IC6J M[K,-SL[W/?JVT(?YOPT38E7VW@LZEL3L+_/F'[W?L(>P9GM'15DD'POD,HR' M/FC>3^SN#FOR+WFUW^'):39*'J(C3]HC/""UK#]>J=<0B>.0V[VG"+[.NDDV MWD[]VM',CK^JLO<>?5'_<)7ZM:O6_P-02P,$% @ 8H'W6-X"5 =J @ M9P< !$ !UM16)GMD/+O\=V8Y4 ':NTA_6E)^=\W[F?Y.Q\V]3H :1B M@L^#)(P#!)R*DO'5/+B]N<+3X'PQ&IU]P/CNT_4270K:-< UNI! -)1HP_0: MZ36@GT+>LP>"OM=$5T(V&"\<[4*TCY*MUAJE<3KV,&^5>4J+9)R0$A.8QGB< MG4Z,%!>X)-.XJ$Y.RJPJ/Z[R+"'CF$X2?%*4,SRF:85G<%K@)([39)Q.II-L MZIQN5:[H&AJ"3&E#!CVV9OQ^ M@-X6LO;X+++F@BCP\$YQ,H!WBG 24M%$MM;X-,T"1+26K.@T7)FF7$)%NEK/ M@X[_[DC-*@:EZ7@-MJ<#P#.S)G(%^BMI0+6$PGL1%R.$;!=8TPJI$7^3U[,*TTXA6-BFR?L M>?\BA_U,C\O!\X[/P3E30,.5>(A*8'9RV=OAU2&X%; 5AC$)YT([OM7TNK9E MO!([A5'9Q'.?_354_DQ>[?X;*^+^5(>W(/^0.1DIIV]?&\?5H':;W2=ZZ_K&AX M6KOG9^?G%+N;7HR> %!+ P04 " !B@?=8W\J*S00* !]5 %0 '5S M;F$M,C R-# W,C-?;&%B+GAM;,U<76_;.A)][Z_@9E]V@3^M4GTT7:9FC=XLF?OY]?JALS%S#- M%J7(5 6P2-\LZB?/].%NG\ M=F;6S]T4)FEW.RN*AM,OM6 \07$WW\Z%BW)73 MSP<+]\I>(0Y/(^E*TL)BJW^X_;$C:REQ3YO!^=,N_W 2[39D%/0%YH4]@]90N!UF6$ MB;Q*RYF9QE2'+$SLWDX("JF4$93$7ADECD)">G(TNHI,NGC^L'UO MSO+Y_"Y+EQW%8AHH&H9*:]LGQ=S^B&(H=6(;*QZS.(P"@L*@KX):$8XLHQ4F M:(+V5U%[5O9+:3!7-STYTG22TTXJ7IIJ]SB:L'82VE37;D-WB56-^NSB)L_, MY[NY-,4TCDDHC3$P0;&!%#$#!<$4QI0I)FF$N&%]U?72^9&%5<.!&@\L ?N+ M:BL/^_4TA)V;E!R(.+AJ;NNFT<9?,52&J">+EXUSFLRFG M 2*884AHDD :)1IR@C5,A$D2*R04$-E7+PW/Q][,+;' $JR_4)KL]ZO$FY/C M[JT?'2=YM(;NI8VFI]&$T4I@4Q7M!NZ2^)"5=L?W*5-Y<9L7=5&Z+$5ISO*[ MK"P>SW)MI@@GH>UQ&.0\L'LWCC&,I4R@"3$U$G&JDM[;MAYX1Y;/,@+0".$7 M4 =ALP96@8 JDO[:ZI/&_8H[<'+<='B(O#B)U(&MEW3[^!]-T YD-V7N\C9? M\;_7VBZ+1>WW2W%1Y#]22V<:H( 9@C34$1*0ABB&@E4=&TT,#R@*%,-NJF\' M&D?N*^R-!;W&=Q5Y1[KZJGMX$KQD[<'?0\R[R0U0<8?CD>6[F]ZV;O?8NPOV MHC!5_VBLE^JT^]-B<6>*J^J@H/B2)+;W"3 30E(,@S!FD ;4MG]APF%"!3,, M&1X1U5>T^\".+%P+#]4&/E@& )81@#J$_MK=F[G]^CUD/MPT/"@53C+NR]%+ MRGN=CR;GOC0W)=W[/>ZR7M^]\G1@^YN]8$RUB)(X,@8:)@VD)!&0AR*&RL0F MED:'2D1]M=R*<&0!/]V3LP0%%A54L/U%VYZ7_4H=S-9-GLY$G22YDXR7#ML] MCB:^G80V%;?;T%UF9_D/4[R7B[(0JNRQC!KVQUL^-0SXSQKHOX=9-JW!>RV7 MIJ?1EDDK@Q.7I'YO^ABW'K7P[3N5SFLU2EI97Z[W9O M5J1B-A6,:(00ASPR%-)(8Q@K:C]G%#&AHR#4M'?;LNW^R$)\!@1K1(>;I+:3 ML5]VPRBZR53$;2L6<"@43I!D+!'4[SRJ 3/R:=02&UAPKP/GUD3U[<2&TO=JQ)R9^Y]" MM1(;?@;5=/MS3J!:J76>/[5;^X^IK^Q;IRQAD4&"P:HD02J-LB4J""'&6MD= M7D0,TJ[3ZR<5KV+P9^* 9<^UH]-'R9OAM M$^7&Z[Y5ZLPZ*L3LD^VC'OYE'J=6#2@.@@A*+36D01)#F4@KD$AQI)/ Q,3Q M-JD7"./4IA4HJ%&!A74M2B_STK<>#6#K58KZ$_6H01UD!I2?EQY'KCP=A+:+ M3I>AN\S>6ZGJ2JX?9^)Z2B.38$9"J&+%(4U"VQ,9@B$.@R#$4M)QDDQKZ%Y2:7H:32*M!#:ET6[@6WD^IK.G M?_J022!-J&!("(-4)!S&841@I!7!/"35/3]N1>?9^3CUIL)S_J>/K3ST+3)^ M[+SJ2Q]B'I5EF\& HK+A;.1ZLDUCNY2TV P<*51CBB_%57Z?39/J-AH6&RBP M(,OM&F?"V.V:E 9S3&3H-T]XQAAYF%"/K?("5-">DX2-_#B.$?Q8#YLA]"+L M/T#8IC1\>K#A\^>,#K9)=P(\ MY+F'W "1=GD>6:I["&X+=M\;!E;-U:_S-#-XJ@QEB(D(4HFM9#75D!O%(*=: M:$P4QAIYUNLI:W&OK+\:J[3ZK;'K*R_VTA)HD(D,4P4XY"24,)8!Q(*%#"4:!:9 M_D?&;0#CB/$9T_'[GEISTE=]_DR]A->7I(?&ULU9IM3^-($L??\RERN;?7I)_L[D8# M*XZ=.:%E=] ,JUW=FZ@?JA-K'1NUS0#?_LJ&[!&8V?/A2'AX$1*[[:K^UR_= M5>6\^^%N4\Z^0&J*NCJ>LT,ZGT'EZU!4J^/YKU<WMX9U+ MY6&=5@M.J5AL1\\?A]^]&'\K^M',&+/HS_XYM"F^-A!ORQ:__WSQV:]A8TE1 M-:VM?&>@*8Z:_N!%[6W;J_X__9I]X089P(=GC7A/G)P6SV($>J M2_@$<=;]__73^8[)F\96]M#7FT5W=G%6(PWH9W]=>W\-Q_.FV%R7L#VV3A"/ MYS=-94D74*JXZ*S]_>'"Q7^-7B=HD)1^DA=XX/'ZSLK_Z0#)C1]O9E M[7<&E9V>]9]7EM9!V1]=!BB6_5U/7=,FZ]LEV$AY5(P(H021,H]$*^6)BYP: M3Z.3TN[.M_.W08=[^1OPAZOZRP)OC&'@HGO3B?$@Q MS#Z*\SN_M]^T*QRZ! M&2%IB,3FF4*WJ2$Z&D=R9Y3F1@>GV2BWGUK;]?II,$^3G]4I0,(%8VO.)O\B ML+NH/HY87-N$-R)^791A>W5,]68?L6KK/2CW$!9T=S[#64=("<+%0U2^.;E^ M9BTNH]"/W$?$+R$5=7A?A1]QG5W&&'"^T1/- )<_&W+B!*Z&+N0N$\8:Y=5> M0K]C=A #?/H,O%[+-X;A?=46[?TG6!6=$E7[B]W 4D8:=<#IB^@MD< IT7GN MB #+)4@J6QP$1#9U(%ZIX"2B?V7O MS@-J5<3BH>1XG$B>@](2ZRV6^PYC&HCS0A PR!(SA7;QS[R#?.#N,BGSL4^ MM)T$)*27>"981"S')K*!BY#T"^8GH0'&KJ M<(S5=$I@G.';C^FJOJV6EH.E("Q10F(Q%<$2;;*<2,V4-R&CU.YC"WEA>! 4 M^CN!XI5Z3@F)/B_ZF"Y3_:6H/"RMBLI$JHGFF4.TA4))L,SB(@#7T4.(V?ZX M>&9]$!SF.X%CC+)3(N2R;EI;_KNX[M-FYSR5*F+:;+':EL$HK,"9)IDS)GBJ M !?#_?&Q8WM8,XM^)WB\7M8WAJ-;]$X3V-YOG\4@/>&1\4S9S+ALW#.MES:'<3#A'N5(&=\8@LL$'<& MB6W_?*Y[M)L^1O1CJ3*:^RQ8$FS$?4TZB4NE$"-@=9 AYR)JN4]$7G@P#)0) M-R[W*O%;;RC@;W!3O&?<715MV3W;%;EVF29=EYY(CS6SI1H(=R%XYZBS;AP> MSRT.PV'"K*? ME@K\J-COF!L6^ FW(U\OWD2^]._O_-I6*^@?Y4=A;0P0",]XQ-Q7,^*\E]UT MC,Z\-MK!7K[X3ZT.8V#"7W:UO=+S4SED+N M2& 2JR'.,F(4;F/""&$B=<:9<_03W2XQ4M!0W-XHE,9$!2R'GC2?1Y]Q'%TP,9@_KP3.SPRB8'-D4$L! A0#% @ 8H'W M6-_*BLT$"@ ?50 !4 ( !:E< '5S;F$M,C R-# W,C-? M;&%B+GAM;%!+ 0(4 Q0 ( &*!]U@!YUA/JP8 -@P 5 M " :%A !U XML 19 usna-20240723_htm.xml IDEA: XBRL DOCUMENT 0000896264 2024-07-23 2024-07-23 false 0000896264 8-K 2024-07-23 USANA HEALTH SCIENCES, INC. UT 001-35024 87-0500306 3838 West Parkway Boulevard Salt Lake City UT 84120 801 954-7100 false false false false Common Stock, $0.001 par value per share USNA NYSE false